GAIN Act Advances in the House

Statement

Date: Sept. 21, 2012

As a result of legislation I authored, the GAIN Act, the FDA this week conferred special status to delafloxacin, a new drug being developed for use in hospitals as a "first-line" antibiotic. The bipartisan GAIN Act, signed into law in July, aims to spur development of new drugs to treat the growing number of "superbugs." It also streamlines and fast-tracks the FDA review process, ensuring patients have access to life-saving treatments. The drug is under development to treat lung infections, including pneumonia and bronchitis, and skin infections.


Source
arrow_upward